Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study

Zhongwei Zhao; Jianfei Tu; Xiaoxi Fan; Jingjing Song; Fazong Wu; Xihui Ying; Jianting Mao; Jiansong Ji

doi:10.21037/tcr.2020.03.64

Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study

Transl Cancer Res. 2020 May;9(5):3191-3202. doi: 10.21037/tcr.2020.03.64.

Authors

Zhongwei Zhao^#^{1

2}, Jianfei Tu^#^{1

2}, Xiaoxi Fan^{1

2}, Jingjing Song^{1

2}, Fazong Wu^{1

2}, Xihui Ying^{1

2}, Jianting Mao^{1

2}, Jiansong Ji^{1

2}

Affiliations

¹ Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.
² Department of Interventional Radiology, Zhejiang University Lishui Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui 323000, China.

^# Contributed equally.

Abstract

Background: This study aimed to explore the efficacy and safety of drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE) with or without iodine-125 (¹²⁵I) seed implantation in treating advanced non-small cell lung cancer (NSCLC) patients.

Methods: A total of 25 advanced NSCLC patients underwent DEB-TACE were consecutively enrolled, among which 17 cases also received ¹²⁵I seed implantation post DEB-TACE treatment. Treatment response, overall survival (OS), biochemical indexes and safety profiles were recorded and analyzed.

Results: Zero (0.0%), 13 (54.2%), 9 (37.5%) and 2 (8.3%) patients realized complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) respectively, and the objective response rate (ORR) and disease control rate (DCR) were 54.2% and 91.7%. The median OS was 12.6 (95% CI: 7.8-17.5) months. No difference of treatment response or OS was observed between DEB-TACE treatment alone and DEB-TACE plus ¹²⁵I seed implantation. Predictive factors analysis revealed that tumor size correlated with worse OS. Besides, chest distress grade and dyspnea grade were decreased after DEB-TACE procedure, while clinical symptoms were not changed after ¹²⁵I seed implantation. The common adverse events (AEs) were fever (32.0%), pain (12.0%) by DEB-TACE treatment, and common AE was pain (26.7%) by ¹²⁵I seed implantation.

Conclusions: DEB-TACE with or without ¹²⁵I seed implantation is effective and tolerable in treating advanced NSCLC patients.

Keywords: Drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE); non-small cell lung cancer (NSCLC); overall survival (OS); safety profiles; treatment response.